Altimmune (ALT) vs Puma Biotechnology (PBYI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Puma Biotechnology (PBYI) has outperformed Altimmune (ALT) over the past year, gaining 90.6% versus a loss of 33.8%. Over five years, PBYI leads with a +64.8% price change compared with -78.4% for ALT. Puma Biotechnology is the larger company by market cap ($514.7 million vs $505.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALT | PBYI |
|---|---|---|
| Share price | $2.60 | $9.97 |
| Market cap | $505.75M | $514.65M |
| 1-day change | -2.26% | +1.63% |
| YTD return | -27.98% | +67.56% |
| 1-year return | -33.84% | +90.63% |
| 5-year return | -78.35% | +64.79% |
| P/E ratio (TTM) | — | 19.55 |
| Forward P/E | — | 28.49 |
| EPS (TTM) | $-0.76 | $0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.44 | $10.10 |
| 52-week low | $2.55 | $4.58 |
| Distance from 52-week high | -59.63% | -1.29% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +558.08% | — |
| Average volume | 4.21M | 320.69K |
| Shares outstanding | 194.52M | 51.62M |
| Employees | 57 | 179 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PBYI has outperformed ALT by 124.5 percentage points over the past year.
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Puma Biotechnology
PBYI stock →Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Health Care · Biotechnology: Pharmaceutical Preparations · 179 employees
ALT vs PBYI FAQ
Which is bigger, Altimmune or Puma Biotechnology?
Puma Biotechnology (PBYI) is larger, with a market capitalization of $514.65M compared with $505.75M for Altimmune (ALT).
Which stock has performed better over the past year, ALT or PBYI?
PBYI returned +90.63% over the past 12 months, compared with -33.84% for ALT (price return, excluding dividends). Past performance does not predict future results.
Are Altimmune and Puma Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.